| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 20, 2017Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity
DUBLIN and VIENNA - June 20, 2017 - Medtronic plc (NSYE: MDT) today announced new data showing that use of its cardiac resynchronization therapy (CRT) devices - with its proprietary AdaptivCRT(TM)...
-
Jun 18, 2017Data Presented as Late Breaking Clinical Trial at EUROPACE 2017
DUBLIN and VIENNA - June 18, 2017 - Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT) today announced that its Reactive...
-
Jun 7, 2017The MiniMed(TM) 670G System Features the Company's Most Advanced SmartGuard(TM)HCL Technology and New Guardian(TM) Sensor 3
DUBLIN - June 7, 2017 - Medtronic plc (NYSE:MDT), today announced the U.S. launch of the MiniMed(TM) 670G system - the world's first Hybrid Closed Loop system for people with type 1 diabetes....
-
Jun 6, 2017
DUBLIN - June 6, 2017 - Medtronic plc (NYSE: MDT) today announced it has received a Health Canada licence for SureTune(TM)3 software for deep brain stimulation (DBS). The latest innovations in the...
-
Jun 6, 2017Medtronic Will Host a Webcast of Its Diabetes Group Analyst and Investor Briefing on Saturday, June 10 from 2 - 4 p.m. PDT
DUBLIN - June 6, 2017 - Medtronic (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 77th Scientific Sessions of...
-
May 31, 2017
DUBLIN - May 31, 2017 - Medtronic plc (NYSE: MDT) recently launched PRODIGY, a 1,650-patient global study, to identify individuals at high risk for opioid induced respiratory depression (OIRD), a...
-
May 25, 2017Q4 Revenue of $7.9 Billion Grew 5% as Reported; 5% at Constant Currency
DUBLIN - May 25, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2017, which ended April 28, 2017. The company reported fourth quarter...
-
May 24, 2017
DUBLIN - May 24, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 38th Annual Goldman Sachs Global Healthcare Conference on...
-
May 24, 2017
DUBLIN - May 24, 2017 - Medtronic plc (NYSE: MDT) today announced that the first patient has been enrolled in the IN.PACT(TM) AV Access Drug-Coated Balloon (DCB) study for use in patients with...
-
May 18, 2017First-Ever Study on 2.0 mm DES, EuroPCR Late-Breaking Data Show Exceptional Deliverability and No Stent Thrombosis for the Resolute Onyx DES
DUBLIN and PARIS- May 18, 2017 - Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year...
-
May 17, 2017Nearly 90 Percent of Patients 71 and Older Met Clinical Guidelines for Remote Monitoring
DUBLIN and CHICAGO- May 17, 2017 - A new Medtronic plc (NYSE: MDT) study shows a high use of app-based remote cardiac monitoring among older patients. Presented at Heart Rhythm 2017, the Heart...
-
May 16, 2017Late-Breaking Real-World Study Results at EuroPCR from CoreValve ADVANCE and Evolut R FORWARD Registries Show Strong Performance Consistent with Data from CoreValve Randomized Clinical Trials
DUBLIN and PARIS - May 16, 2017 - Medtronic plc (NYSE:MDT) today unveiled new positive data on the self-expanding CoreValve(TM) platform from the CoreValve ADVANCE and Evolut R FORWARD clinical...
-
May 16, 2017
DUBLIN - May 16, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 2017 Jefferies Global Healthcare Conference on Thursday, June...
-
May 15, 2017EffectivCRT(TM)and AdaptivCRT(TM) Exclusives Featured in Heart Rhythm 2017 Presentations
DUBLIN - May 15, 2017 - Medtronic plc (NYSE: MDT) today announced new data supporting the clinical performance of the company's exclusive EffectivCRT(TM) Diagnostic and AdaptivCRT(TM) algorithm in...
-
May 12, 2017Results from the REVEAL AF Study Show That AF Would Have Gone Undetected in the Majority of Patients at High-Risk for AF and Stroke If Cardiac Monitoring Was Limited to 30 Days
DUBLIN and CHICAGO - May 12, 2017 - Medtronic plc (NYSE: MDT) today announced results from a new clinical study showing Medtronic Insertable Cardiac Monitors (ICM) detected a high incidence of...
-
May 11, 2017HRS Late-Breaking Trial Reveals High Implant Success Rate and Low Early Major Complication Rate for the Medtronic Micra® Transcatheter Pacing System (TPS)
DUBLIN and CHICAGO - May 11, 2017 - Medtronic plc (NYSE: MDT) today announced preliminary results for the Medtronic Micra® Transcatheter Pacing System (TPS) Post-Approval Registry, revealing a...
-
May 10, 2017Portfolio of Next Generation Heart Failure Devices Offers Effective Pacing and Access to the Most Advanced Diagnostic Imaging Procedures
DUBLIN - May 10, 2017 - Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps)...
-
May 9, 2017
DUBLIN - May 9, 2017 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the fourth quarter and fiscal year 2017 on Thursday, May 25, 2017. A news release will be...
-
May 1, 2017Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S.
DUBLIN – May 1, 2017 – Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx™ Drug-Eluting Stent (DES). The...
-
Apr 26, 2017Presented at Charing Cross, Five-Year Clinical Data from Global ENGAGE Registry Support Endurant II's Market-Leading Position Worldwide
DUBLIN and LONDON - April 26, 2017 - Medtronic plc (NYSE:MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and...
-
Apr 25, 2017
DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today reinforced consistent results for its IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with two new sub-analyses from the...
-
Apr 25, 2017Three-Year VeClose Trial and One-Year WAVES Study Data Presented at Charing Cross
DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results...
-
Apr 24, 2017New Platform to Offer Flexibility, Ease of Use, Improved Registration and Advanced Visualization for Custom Procedural Workflows
DUBLIN and LOS ANGELES - April 24, 2017 - Medtronic plc (NYSE:MDT) today launched its new StealthStation(TM) technology at the American Academy of Neurological Surgeons (AANS) annual conference in...
-
Apr 20, 2017
DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) announced its sponsorship of the 23rdParkinson's Unity Walk which will be held on April 22, 2017, in New York City. Beginning at 8:30 a.m. EDT,...
-
Apr 20, 2017New Data from the Global ENGAGE Registry, IN.PACT Admiral Global Study, and VeClose Study Among Key Presentations
LONDON and DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) today announced key clinical studies for its leading vascular interventional portfolio will be featured at the annual 2017 Charing...